KPRX vs. TTPH, JAGX, KZR, KRON, LEXX, DRRX, GANX, NBRV, CASI, and NXTC
Should you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Tetraphase Pharmaceuticals (TTPH), Jaguar Health (JAGX), Kezar Life Sciences (KZR), Kronos Bio (KRON), Lexaria Bioscience (LEXX), DURECT (DRRX), Gain Therapeutics (GANX), Nabriva Therapeutics (NBRV), CASI Pharmaceuticals (CASI), and NextCure (NXTC). These companies are all part of the "medical" sector.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
Kiora Pharmaceuticals has a consensus target price of $2.00, suggesting a potential upside of 305.68%. Given Tetraphase Pharmaceuticals' higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Tetraphase Pharmaceuticals.
Kiora Pharmaceuticals has lower revenue, but higher earnings than Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals received 371 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 68.42% of users gave Kiora Pharmaceuticals an outperform vote while only 67.13% of users gave Tetraphase Pharmaceuticals an outperform vote.
In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Tetraphase Pharmaceuticals. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for Tetraphase Pharmaceuticals. Tetraphase Pharmaceuticals' average media sentiment score of 0.96 beat Kiora Pharmaceuticals' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.
42.3% of Tetraphase Pharmaceuticals shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 5.7% of Tetraphase Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Kiora Pharmaceuticals has a net margin of 0.00% compared to Kiora Pharmaceuticals' net margin of -798.18%. Tetraphase Pharmaceuticals' return on equity of 17.90% beat Kiora Pharmaceuticals' return on equity.
Tetraphase Pharmaceuticals has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
Summary
Kiora Pharmaceuticals beats Tetraphase Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Kiora Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiora Pharmaceuticals Competitors List
Related Companies and Tools
